GlassScriptPhysician profile
Richard Kenneth Capling
NPI 1265450217
$30,828.90
in general payments reported to CMS, 2019-2025
24 companies · $3,282 in 2025
The $3,282 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.18 · 2020: $84.19 · 2021: $152 · 2022: $143 · 2023: $296 · 2024: $27K · 2025: $3,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $1,591 · Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,427.50 |
| Travel and Lodging | $1,591.26 |
| Food and Beverage | $1,416.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,587.60 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $4,101.85 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Travere Therapeutics, INC. | $242.00 | 2022-2025 | |
| Novo Nordisk INC | $125.89 | 2022-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $86.24 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $76.96 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $56.20 | 2023-2024 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $54.98 | 2021-2024 | Farxiga, Airsupra |
| Amgen INC. | $53.36 | 2024 | Tavneos |
| Novartis Pharmaceuticals Corporation | $51.87 | 2024-2025 | |
| Corcept Therapeutics | $50.15 | 2022-2023 | Korlym |
| Fresenius USA Marketing, INC. | $48.17 | 2024-2025 | Velphoro, Nxstage System One |
| Baxter Healthcare | $47.52 | 2020 | |
| Calliditas Therapeutics US INC. | $43.95 | 2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $34.42 | 2021-2025 | Benlysta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $29.19 | 2020-2021 | |
| Ardelyx, INC. | $25.81 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $21.20 | 2023 | |
| Neurocrine Biosciences, INC. | $18.70 | 2023 | Ingrezza |
| Merck Sharp & Dohme LLC | $17.87 | 2021 | |
| Mannkind Corporation | $14.43 | 2023 | Afrezza |
| Mallinckrodt Enterprises LLC | $14.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.67 | 2024 | Xifaxan |
| Medtronic, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Capling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.